REVB
Revelation Biosciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Strong sell
-60/100
Last price
0.75
▼ 0.02 (3.20%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
0.78
Day high
0.80
Day low
0.75
Volume
34.67K
Market cap
$3.00M
P/E (TTM)
0.16
52W range
0.75 – 6.76
Trailing performance
Returnvs SPY
1W
-7.62%
-9.6%
1M
-25.54%
-26.7%
3M
-22.31%
-26.8%
6M
-33.45%
-51.6%
YTD
-76.50%
-90.7%
1Y
-87.47%
-103.9%
3Y
-99.98%
-182.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on REVB open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
491.39K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | CHAWLA LAKHMIR S Director |
STOCK | 32.01K | $0 | Direct |
| Aug 17, 26 | CARVER JENNIFER A Director |
STOCK | 32.01K | $0 | Direct |
| Aug 17, 26 | ROLKE JAMES M Chief Executive Officer |
STOCK | 208.08K | $0 | Direct |
| Aug 17, 26 | ZYGMONT CHESTER STANLEY III Chief Financial Officer |
STOCK | 208.07K | $0 | Direct |
| Aug 17, 26 | ROPER JESS Director |
STOCK | 32.01K | $0 | Direct |
| Aug 17, 26 | ZYGMONT CHESTER STANLEY III Chief Financial Officer |
STOCK | 208.07K | $0 | Direct |
| Jan 8, 26 | CHAWLA LAKHMIR S Director |
STOCK | 41.98K | $37.78K | Direct |
| Jan 8, 26 | CARVER JENNIFER A Director |
STOCK | 41.98K | $37.78K | Direct |
| Jan 8, 26 | ROLKE JAMES M Chief Executive Officer |
STOCK | 532.83K | $479.55K | Direct |
| Jan 8, 26 | ZYGMONT CHESTER STANLEY III Chief Financial Officer |
STOCK | 78.14K | $70.33K | Indirect |
| Jan 8, 26 | ROPER JESS Director |
STOCK | 41.98K | $37.78K | Direct |
| Oct 29, 25 | CHAWLA LAKHMIR S Director |
STOCK | 15.63K | $20.00K | Direct |
| Oct 29, 25 | CARVER JENNIFER A Director |
STOCK | 15.63K | $20.00K | Direct |
| Oct 29, 25 | ROLKE JAMES M Chief Executive Officer |
STOCK | 390.61K | $499.99K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARVER JENNIFER A |
Director | 44.77K | Stock Award(Grant) |
CHAWLA LAKHMIR S |
Director | 44.17K | Stock Award(Grant) |
ROLKE JAMES M |
Chief Executive Officer | 422.81K | Stock Award(Grant) |
ROPER JESS |
Director | 44.84K | Stock Award(Grant) |
TIDMARSH GEORGE F |
Director | — | Stock Award(Grant) |
ZYGMONT CHESTER STANLEY III |
Chief Financial Officer | 300.14K | Stock Award(Grant) |
Fundamentals
Market cap$3.00M
Enterprise value$-7.75M
Revenue (TTM)—
Gross profit—
EBITDA$-11.24M
Net income$-19.20M
EPS (TTM)$4.60
Free cash flow$-5.78M
Total cash$11.48M
Total debt$739.92K
Book value / share$2.58
Shares outstanding3.98M
Float3.05M
Short % of float0.01%
Dividend yield0.00%
Beta (5Y)-0.06
Valuation & profitability ratios
Trailing P/E0.16
Forward P/E-0.26
PEG ratio—
Price / sales—
Price / book0.29
EV / revenue—
EV / EBITDA0.69
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-154.77%
Return on assets-78.73%
Debt / equity7.35
Current ratio6.21
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $4.06M | $3.55M | $4.15M | $5.38M | +14.5% |
| Selling, general & admin | $5.01M | $4.43M | $4.51M | $5.49M | +13.1% |
| Total operating expense | $9.07M | $7.98M | $8.66M | $10.86M | +13.7% |
| Operating income | -$9.07M | -$7.98M | -$8.66M | -$10.86M | -13.7% |
| Pre-tax income | -$8.91M | -$15.04M | -$120.25K | -$10.83M | +40.7% |
| Net income | -$8.91M | -$15.04M | -$120.25K | -$10.83M | +40.7% |
| Net income to common | -$14.87M | -$15.04M | -$120.25K | -$10.83M | +1.2% |
| Basic EPS | -23.95 | -1,052.16 | -87.33 | -91,775.84 | +97.7% |
| Diluted EPS | -23.95 | -1,052.16 | -87.33 | -91,775.84 | +97.7% |
| EBIT | -$9.07M | -$7.98M | -$8.66M | -$10.86M | -13.7% |
| EBITDA | -$9.04M | -$7.95M | -$8.63M | -$10.84M | -13.8% |
| Basic shares | 620.78K | 14.29K | 1.38K | 118 | +4,243.6% |
| Diluted shares | 620.78K | 14.29K | 1.38K | 118 | +4,243.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $10.70M | $6.50M | $11.99M | $5.25M | — | +64.6% |
| Cash & short-term investments | $10.70M | $6.50M | $11.99M | $5.25M | — | +64.6% |
| Total current assets | $10.81M | $6.57M | $12.15M | $5.41M | — | +64.7% |
| Property, plant & equipment | $740.36K | $56.33K | $65.08K | $90.13K | — | +1,214.3% |
| Total assets | $11.58M | $6.62M | $12.21M | $5.50M | — | +74.9% |
| Total current liabilities | $2.00M | $1.91M | $5.56M | $4.45M | — | +4.4% |
| Total debt | $746.78K | $0 | — | $0 | $16.75K | — |
| Total liabilities | $2.72M | $1.91M | $5.56M | $4.45M | — | +42.2% |
| Retained earnings | -$49.42M | -$40.51M | -$25.47M | -$25.35M | — | -22.0% |
| Shareholder equity | $8.86M | $4.71M | $6.65M | $1.05M | — | +88.2% |
| Working capital | $8.81M | $4.65M | $6.58M | $962.32K | — | +89.5% |
| Net tangible assets | $8.86M | $4.71M | $6.65M | $1.05M | — | +88.2% |
| Shares issued | 1.58M | 43.52K | 1.38K | 118 | — | +3,539.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$8.91M | -$15.04M | -$120.25K | -$10.83M | — | +40.7% |
| Depreciation & amortisation | $27.06K | $27.92K | $25.05K | $25.05K | — | -3.1% |
| Stock-based compensation | $595.37K | $168.85K | $155.72K | $301.12K | — | +252.6% |
| Change in working capital | -$6.04K | -$3.42M | $982.13K | -$730.97K | — | +99.8% |
| Operating cash flow | -$8.27M | -$18.32M | -$7.29M | -$11.22M | — | +54.9% |
| Capital expenditure | — | -$19.17K | — | — | -$131.96K | — |
| Investing cash flow | $0 | -$19.17K | $0 | $0 | — | +100.0% |
| Share buybacks | — | $0 | -$5.00K | — | — | — |
| Financing cash flow | $12.47M | $12.85M | $14.03M | $15.20M | — | -2.9% |
| Free cash flow | -$8.27M | -$18.34M | -$7.29M | -$11.22M | — | +54.9% |
| End cash position | $10.70M | $6.50M | $11.99M | $5.25M | — | +64.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $1.92M | $1.38M | $964.19K | $922.86K | $1.32M | +39.3% |
| Selling, general & admin | $1.74M | $1.72M | $1.61M | $1.02M | $1.14M | +1.6% |
| Total operating expense | $3.66M | $3.09M | $2.57M | $1.94M | $2.46M | +18.4% |
| Operating income | -$3.66M | -$3.09M | -$2.57M | -$1.94M | -$2.46M | -18.4% |
| Pre-tax income | -$3.32M | -$3.01M | -$2.51M | -$1.91M | -$2.44M | -10.4% |
| Net income | -$3.32M | -$3.01M | -$2.51M | -$1.91M | -$2.44M | -10.4% |
| Net income to common | -$3.32M | -$8.69M | -$2.51M | -$4.68M | -$5.63M | +61.8% |
| Basic EPS | -0.87 | -2.71 | -1.65 | -7.08 | -28.04 | +67.9% |
| Diluted EPS | -0.87 | -2.71 | -1.65 | -7.08 | -28.04 | +67.9% |
| EBIT | -$3.66M | -$3.09M | -$2.57M | -$1.94M | -$2.46M | -18.4% |
| EBITDA | -$3.65M | -$3.09M | -$2.57M | -$1.94M | -$2.45M | -18.4% |
| Basic shares | 3.83M | 3.21M | 1.52M | 661.18K | 200.67K | +19.4% |
| Diluted shares | 3.83M | 3.21M | 1.52M | 661.18K | 200.67K | +19.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $11.48M | $14.11M | $10.70M | $12.71M | $5.17M | -18.6% |
| Cash & short-term investments | $11.48M | $14.11M | $10.70M | $12.71M | $5.17M | -18.6% |
| Total current assets | $11.68M | $14.21M | $10.81M | $12.83M | $5.36M | -17.7% |
| Property, plant & equipment | $782.48K | $807.31K | $740.36K | $23.92K | $35.17K | -3.1% |
| Total assets | $12.50M | $15.04M | $11.58M | $12.86M | $5.40M | -16.9% |
| Total current liabilities | $1.88M | $1.42M | $2.00M | $1.85M | $1.57M | +32.7% |
| Total debt | $739.92K | $759.04K | $746.78K | — | — | -2.5% |
| Total liabilities | $2.43M | $2.06M | $2.72M | $1.85M | $1.57M | +18.3% |
| Retained earnings | -$55.75M | -$52.43M | -$49.42M | -$46.91M | -$45.00M | -6.3% |
| Shareholder equity | $10.07M | $12.99M | $8.86M | $11.00M | $3.83M | -22.5% |
| Working capital | $9.80M | $12.79M | $8.81M | $10.98M | $3.79M | -23.3% |
| Net tangible assets | $10.07M | $12.99M | $8.86M | $11.00M | $3.83M | -22.5% |
| Shares issued | 3.91M | 3.91M | 1.58M | 896.49K | 383.66K | 0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$3.32M | -$3.01M | -$2.51M | -$1.91M | -$2.44M | -10.4% |
| Depreciation & amortisation | $8.31K | $7.20K | $5.85K | $6.76K | $7.22K | +15.4% |
| Stock-based compensation | $401.42K | $471.00K | $370.17K | $874 | $873 | -14.8% |
| Change in working capital | $300.31K | -$739.70K | $149.45K | $306.76K | $517.05K | +140.6% |
| Operating cash flow | -$2.56M | -$3.21M | -$1.97M | -$1.59M | -$1.92M | +20.5% |
| Capital expenditure | -$39.63K | -$71.88K | — | — | — | +44.9% |
| Investing cash flow | -$39.63K | -$71.88K | $0 | $0 | $0 | +44.9% |
| Financing cash flow | -$33.80K | $6.70M | -$41.17K | $9.12M | $3.39M | -100.5% |
| Free cash flow | -$2.60M | -$3.29M | -$1.97M | -$1.59M | -$1.92M | +21.0% |
| End cash position | $11.48M | $14.11M | $10.70M | $12.71M | $5.17M | -18.6% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.83 | -0.87 | -4.8% |
| Mar 2026 | -1.15 | -2.71 | -135.6% |
| Dec 2025 | -3.66 | -1.65 | +54.9% |
| Sep 2025 | -5.34 | -7.08 | -32.6% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.88 | 2 | $0 | 0.0% |
| Next quarter | -0.86 | 2 | $0 | 0.0% |
| Current year | -5.19 | 2 | $0 | 0.0% |
| Next year | -2.89 | 2 | $0 | 0.0% |
Analyst targets & ownership
Mean target$17.75
High target$19.50
Low target$16.00
Implied upside2259.74%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 1
Hold0
Sell / Strong sell0 / 0
Held by insiders12.34%
Held by institutions12.89%
Institutions holding14
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
0.83
-8.91% from price
SMA 20
0.89
-15.88% from price
SMA 50
0.99
-24.19% from price
SMA 100
1.02
-26.17% from price
SMA 200
1.42
-47.22% from price
EMA 12
0.83
-9.84% from price
EMA 26
0.90
-16.41% from price
EMA 50
0.96
-21.60% from price
RSI (14)
26.8
Oversold
MACD (12,26,9)
-0.07
Hist -0.01
ATR (14)
0.06
7.64% of price
Realised vol 30D
56.2%
Annualised
Bollinger upper
1.06
20, 2σ
Bollinger lower
0.73
20, 2σ
50 / 200 cross
Death
0.99 vs 1.42
Trend bias
Below 200
-47.22%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.41
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
56.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-87.2%
Peak to trough
Max drawdown 5Y
-100.0%
Peak to trough
ATR 14
0.06
7.64% of price
Beta (reported)
-0.06
5Y monthly, from filing
Short interest
Shares short
256
Prior 15.39K
Change vs prior
-98.3%
Shorts covering
% of float
0.01%
Normal
% of shares out
0.01%
Against total outstanding
Days to cover
0.0
Liquid
Float
3.05M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:4
Split dateJan 28, 2026
SEC filings
Corporate Changes & Voting Matters
8-K · 2026-08-19
Corporate Changes & Voting Matters
8-K · 2026-08-06
Trading Registrations
8-A12B · 2026-07-13
Corporate Changes & Voting Matters
8-K · 2026-06-24
Corporate Changes & Voting Matters
8-K · 2026-06-01
Proxy Statements
DEF 14A · 2026-05-11
Corporate Changes & Voting Matters
8-K · 2026-05-07
Offering Registrations
S-8 · 2026-04-15
Headlines
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
Business Wire · 49d ago
REVB Approaching a Critical Inflection Point
Zacks Small Cap Research · 61d ago
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
ACCESS Newswire · 61d ago
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
ACCESS Newswire · 65d ago
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ACCESS Newswire · 78d ago
Revelation Biosciences Adopts Stockholder Rights Plan
MT Newswires · 88d ago
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
ACCESS Newswire · 89d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.